INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BiohavenFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Biohaven To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Urges Investors in XPLR Infrastructure, Centene, Biohaven, or Capricor to Inquire About Their Rights in Class Action LawsuitsIf you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648
September 12, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BHVNSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
September 12, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BHVNNEW YORK - July 24, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. (
NYSE: BHVN) of a class action securities lawsuit.
Deadline Alert: Biohaven Ltd. (BHVN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Glancy Prongay & Murray LLP reminds investors of the upcoming September 12, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Biohaven Ltd. (“Biohaven” or the “Company”) (
NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the “Class Period”).
Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers – BHVNNEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biohaven Ltd. (“Biohaven” or the “Company”) (
NYSE: BHVN) and certain officers. The class action, filed in the United States District Court for the District of Connecticut, and docketed under 25-cv-01120, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biohaven securities between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 sand Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Deadline Approaching: Biohaven Ltd. (BHVN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Law Offices of Howard G. Smith reminds investors of the upcoming September 12, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Biohaven Ltd. (“Biohaven” or the “Company”) (
NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the “Class Period”).
BHVN Class Action Alert: Robbins LLP Reminds Biohaven Ltd. Stockholders of the Lead Plaintiff Deadline in the Class Action Against BHVNSAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Biohaven Ltd. (
NYSE: BHVN) securities between March 24, 2023 and May 14, 2025. Biohaven is a biopharmaceutical company that discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology. The Company is developing, among other product candidates, troriluzole for the treatment of spinocerebellar ataxia (“SCA”), among other indications, as well as BHV-7000 for the treatment of bipolar disorder, among other indications.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Biohaven Ltd. (BHVN) Investors To Inquire About Securities Fraud Class Action
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Biohaven Ltd. (“Biohaven” or the “Company”) (
NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the “Class Period”). Biohaven investors have until September 12, 2025 to file a lead plaintiff motion.
Investors in Biohaven Ltd. Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVNSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Investors in Biohaven Ltd. Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVNNEW YORK - July 21, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. (
NYSE: BHVN) of a class action securities lawsuit.
BHVN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Biohaven Ltd. Investors With Substantial Losses Have Opportunity to Lead Class Action LawsuitNEW YORK - July 18, 2025 ( NEWMEDIAWIRE ) - Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biohaven Ltd. (“Biohaven” or “the Company”) (
NYSE: BHVN) and certain of its officers.
Law Offices of Frank R. Cruz Encourages Biohaven Ltd. (BHVN) Investors To Inquire About Securities Fraud Class Action
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Biohaven Ltd. (“Biohaven” or the “Company”) (
NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the “Class Period”). Biohaven investors have until September 12, 2025 to file a lead plaintiff motion.
Law Offices of Howard G. Smith Encourages Biohaven Ltd. (BHVN) Investors To Inquire About Securities Fraud Class Action
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Biohaven Ltd. (“Biohaven” or the “Company”) (
NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the “Class Period”). Biohaven investors have until September 12, 2025 to file a lead plaintiff motion.
Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers – BHVNNEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biohaven Ltd. (“Biohaven” or the “Company”) (
NYSE: BHVN) and certain officers. The class action, filed in the United States District Court for the District of Connecticut, and docketed under 25-cv-01120, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biohaven securities between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 sand Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
BIOHAVEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biohaven Ltd. and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Biohaven (BHVN) To Contact Him Directly To Discuss Their Options
BHVN Investor Notice: Robbins LLP Reminds Biohaven Ltd. Stockholders of the Securities Fraud Class Action LawsuitSAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Biohaven Ltd. (
NYSE: BHVN) securities between March 24, 2023 and May 14, 2025. Biohaven is a biopharmaceutical company that discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology. The Company is developing, among other product candidates, troriluzole for the treatment of spinocerebellar ataxia (“SCA”), among other indications, as well as BHV-7000 for the treatment of bipolar disorder, among other indications.
Securities Fraud Investigation Into Biohaven Ltd. (BHVN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Biohaven Ltd. (“Biohaven” or the “Company”) (
NYSE: BHVN) investors concerning the Company’s possible violations of the federal securities laws.
